You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Psoriasis and Spondyloarthritides: The Evolving Biologics Landscape

Rapid advances in biologic therapies have transformed the treatment of psoriasis and inflammatory joint diseases. Agents targeting the interleukin (IL)-23/IL-17 pathway have now the potential to improve both musculoskeletal and skin outcomes. Early identification and treatment initiation are crucial for successful outcomes in psoriasis and spondyloarthritides. Physicians must understand not only the rationale for the development of newer biologic therapies but also the factors influencing biologic selection for individual patients in clinical practice.

Supported by an independent educational grant from UCB Pharma, Inc.

CME Activities

SPONDYLOARTHRITIDES
PSORIASIS
IN-LANGUAGE EDUCATION RESOURCES

Resources

Steering Committee

Iain B. McInnes, FRCP, PhD
Iain B. McInnes, FRCP, PhD

Steering Committee Chair

Professor of Medicine
University of Glasgow
Glasgow, Scotland

Xenofon Baraliakos, MD, PhD
Xenofon Baraliakos, MD, PhD

Professor of Internal Medicine and Rheumatology
Ruhr-University Bochum
Bochum, Germany

Andrew Blauvelt, MD, MBA
Andrew Blauvelt, MD, MBA

President
Oregon Medical Research Center
Portland, Oregon, United States

Lianne S. Gensler, MD
Lianne S. Gensler, MD

Professor of Medicine
University of California
San Francisco
San Francisco, California, United States

Mark G. Lebwohl, MD
Mark G. Lebwohl, MD

Professor and Waldman Chair
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York, United States

Helena Marzo-Ortega, MRCP, PhD
Helena Marzo-Ortega, MRCP, PhD

Consultant Rheumatologist
Leeds Teaching Hospitals Trust
Associate Professor
University of Leeds
Leeds, United Kingdom

Joseph F. Merola, MD, MMSc
Joseph F. Merola, MD, MMSc

Associate Professor
Harvard Medical School
Boston, Massachusetts, United States

Christopher T Ritchlin, MD, MPH
Christopher T Ritchlin, MD, MPH

Professor and Chief
Division of Allergy, Immunology and Rheumatology
University of Rochester Medical Center
Rochester, New York, United States

Richard B. Warren, MD
Richard B. Warren, MD

Consultant Dermatologist
Salford Royal NHS Foundation Trust
Director
Dermatopharmacology Unit
The University of Manchester
Manchester, United Kingdom